DCF Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

DCF Advisers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,500	Closed	-$986K	–	105
2023 Q3	$986K	Buy	+13,500	New	+$1.08M	0.54%	42
2023 Q1	–	Sell	-3,500	Closed	-$291K	–	79
2022 Q4	$291K	Buy	+3,500	New	+$283K	0.2%	55
2022 Q3	–	Sell	-10,000	Closed	-$743K	–	94
2022 Q2	$743K	Buy	+10,000	New	+$751K	0.44%	43

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

DCF Advisers's XBI Position: Q4 2023 in Review

DCF Advisers sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 13,500 shares — an estimated $986K sold.

DCF Advisers first reported a position in XBI in Q2 2022 and held it in 3 quarters. The position peaked at $986K in Q3 2023. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

DCF Advisers reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
DCF Advisers sold 13,500 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $986K.
DCF Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 3 quarters.
DCF Advisers's State Street SPDR S&P Biotech ETF position peaked at $986K in Q3 2023.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on DCF Advisers's 13F filing for Q4 2023, filed 13 Feb 2024.